PTCT - PTC Therapeutics Inc Stock Price, Fair Value and News

25.38USD-0.59 (-2.27%)Market Closed

Market Summary

USD25.38-0.59

Market Closed

-2.27%

PTCT Stock Price

View Fullscreen

PTCT RSI Chart

PTCT Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-3.18

Price/Sales (Trailing)

2.12

EV/EBITDA

-3.97

Price/Free Cashflow

-10.65

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-74.23%

Return on Equity

76.55%

Return on Assets

-33.05%

Free Cashflow Yield

-9.39%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

937.8M

Rev. Growth (Yr)

83.41%

Rev. Growth (Qtr)

56.2%

PTCT Earnings

Earnings (TTM)

-626.6M

Earnings Growth (Yr)

8.83%

Earnings Growth (Qtr)

-17.16%

Breaking Down PTCT Revenue

Last 7 days

1.1%

Last 30 days

-10.7%

Last 90 days

-7.1%

Trailing 12 Months

-52.9%

How does PTCT drawdown profile look like?

PTCT Financial Health

Current Ratio

2.02

Debt/Equity

-0.35

Debt/Cashflow

-0.56

PTCT Investor Care

Shares Dilution (1Y)

3.78%

Diluted EPS (TTM)

-8.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	770.4M	818.7M	798.2M	937.8M
2022	569.4M	618.2M	696.6M	698.8M
2021	430.4M	471.9M	492.2M	538.6M
2020	321.7M	311.4M	358.4M	380.8M
2019	261.8M	278.5M	296.4M	307.0M
2018	203.7M	224.5M	236.3M	264.2M
2017	90.3M	122.5M	141.3M	174.1M
2016	48.2M	57.0M	70.2M	82.7M
2015	23.5M	28.6M	36.7M	36.8M
2014	36.8M	31.6M	17.0M	25.2M
2013	28.6M	27.8M	36.9M	34.7M
2012	113.1M	115.9M	36.7M	33.9M
2011	0	0	0	105.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of PTC Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	klein matthew b.	sold	-83,668	24.894	-3,361	chief executive officer
Apr 17, 2024	pauwels eric	sold	-19,781	25.135	-787	chief executive officer
Apr 17, 2024	klein matthew b.	sold	-32,851	25.135	-1,307	chief executive officer
Apr 02, 2024	golden lee scott	sold	-14,922	28.37	-526	evp & chief medical officer
Feb 15, 2024	steele glenn jr md phd	acquired	-	-	4,000	-
Feb 15, 2024	golden lee scott	acquired	-	-	22,600	chief medical officer
Feb 15, 2024	utter christine marie	acquired	-	-	16,900	svp, chief accounting officer
Feb 15, 2024	schmertzler michael	acquired	-	-	8,000	-
Feb 15, 2024	boulding mark elliott	acquired	-	-	21,200	exec. vp and clo
Feb 15, 2024	gravier pierre	acquired	-	-	22,100	chief financial officer

Which funds bought or sold PTCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	new	-	45,788	45,788	-%
Apr 18, 2024	Hexagon Capital Partners LLC	added	9.09	4,086	31,068	0.01%
Apr 18, 2024	SJS Investment Consulting Inc.	unchanged	-	11.00	204	-%
Apr 18, 2024	Diversified Trust Co	added	2.08	30,313	421,775	0.01%
Apr 15, 2024	WEST PACES ADVISORS INC.	unchanged	-	1,530	29,090	0.01%
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-165	-	-%
Apr 05, 2024	GAMMA Investing LLC	added	34.33	870	2,618	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	23.06	72,305	314,172	-%
Apr 05, 2024	CWM, LLC	added	41.18	-	1,000	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-762	-	-%

Are Funds Buying or Selling PTCT?

Are funds buying PTCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PTCT

No. of Funds

Unveiling PTC Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.10%	6,864,000	SC 13G
Feb 14, 2024	rtw investments, lp	9.8%	7,423,970	SC 13G/A
Feb 13, 2024	vanguard group inc	11.66%	8,800,843	SC 13G/A
Feb 08, 2024	wellington management group llp	13.01%	9,816,603	SC 13G/A
Jan 24, 2024	state street corp	6.14%	4,633,955	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Jan 08, 2024	blackrock inc.	10.2%	7,668,871	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Oct 30, 2023	camber capital management lp	5.31%	2,013	SC 13G
Feb 14, 2023	rtw investments, lp	7.7%	5,615,387	SC 13G/A

Recent SEC filings of PTC Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	4	Insider Trading
Apr 19, 2024	144	Notice of Insider Sale Intent
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 04, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Feb 29, 2024	10-K	Annual Report
Feb 29, 2024	8-K	Current Report

Peers (Alternatives to PTC Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-0.89%	-25.81%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.46%	-30.31%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	5.17%	-8.18%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-8.90%	-30.41%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-13.99%	-44.77%	-10.87	14.48	425.83%	18.94%
BBIO	4.4B	-	-15.28%	57.81%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-11.84%	-2.48%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-11.98%	-22.42%	-9.98	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.29%	-15.38%	-45.68	3.85	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.94%	-8.31%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-12.98%	-52.88%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	7.90%	326.47%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-13.94%	-3.10%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	63.30%	36.92%	-0.23	2.14	-13.45%	66.37%

PTC Therapeutics Inc News

Latest updates

PTC Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	56.2%	307,056,000	196,576,000	213,808,000	220,382,000	167,412,500	217,127,000	165,526,000	148,735,000	165,230,500	138,743,000	116,676,000	117,942,000	118,864,000	118,404,000	75,239,000	68,259,000	96,459,000	71,416,000	85,522,000	53,583,000	85,833,000
Operating Expenses	-4.3%	301,236,000	314,740,000	423,351,000	337,997,000	367,752,000	285,314,000	257,888,000	235,257,000	249,958,500	231,819,000	215,169,000	216,090,000	215,238,000	173,535,000	262,512,000	161,250,000	169,243,000	131,891,000	124,280,000	122,723,000	131,476,000
S&GA Expenses	-5.7%	76,291,000	80,886,000	88,449,000	86,914,000	92,717,500	80,118,000	79,892,000	73,271,000	86,548,000	69,252,000	68,878,000	61,095,000	75,456,000	57,840,000	53,659,000	58,209,000	63,497,500	49,284,000	49,215,000	40,544,000	48,666,000
R&D Expenses	-26.1%	121,353,000	164,212,000	185,874,000	195,124,000	188,693,500	165,462,000	157,263,000	140,078,000	149,844,000	130,845,000	125,482,000	134,513,000	118,013,000	92,998,000	176,525,000	90,107,000	81,831,000	63,076,000	59,979,000	52,566,000	53,646,500
EBITDA Margin	27.1%	-0.45	-0.62	-0.60	-0.56	-0.63	-0.60	-0.71	-0.75	-0.83	-0.76	-0.62	-0.84	-	-	-	-	-	-	-	-	-
Interest Expenses	-82.0%	2,111,000	11,710,000	9,354,000	12,956,000	5,784,000	4,406,000	2,143,000	6,130,000	-1,000	4,407,000	-	5,182,000	-	4,516,000	408,000	4,878,000	651,000	3,931,000	-	3,111,000	846,000
Income Taxes	96.3%	-1,259,000	-33,620,000	-38,596,000	3,969,000	-18,804,000	-17,893,000	3,392,000	4,835,000	4,657,500	-36,000	488,000	451,000	12,634,000	22,288,000	84,000	222,000	10,644,000	-344,000	774,000	576,000	-993,500
Earnings Before Taxes	5.7%	-157,051,000	-166,590,000	-237,479,000	-134,990,000	-189,693,000	-127,208,000	-148,695,000	-121,891,000	-138,607,500	-133,660,000	-117,882,000	-128,191,000	-61,720,000	-47,404,000	-181,343,000	-112,465,000	-67,033,000	-60,341,000	-41,015,000	-71,537,000	-49,323,000
EBT Margin	18.7%	-0.74	-0.91	-0.84	-0.78	-0.84	-0.77	-0.88	-0.90	-0.96	-0.90	-0.75	-0.97	-	-	-	-	-	-	-	-	-
Net Income	-17.2%	-155,792,000	-132,970,000	-198,883,000	-138,959,000	-170,889,000	-109,315,000	-152,087,000	-126,726,000	-143,265,000	-133,624,000	-118,370,000	-128,642,000	-74,354,000	-69,692,000	-181,427,000	-112,687,000	-77,677,000	-59,997,000	-41,789,000	-72,113,000	-48,330,000
Net Income Margin	16.9%	-0.67	-0.80	-0.75	-0.74	-0.80	-0.76	-0.90	-0.92	-0.97	-0.92	-0.83	-1.05	-	-	-	-	-	-	-	-	-
Free Cashflow	-407.1%	-105,854,000	-20,876,000	-20,365,000	-39,761,000	-174,585,000	-43,427,000	-63,942,000	-106,716,000	-77,566,000	-57,034,000	-39,119,000	-105,826,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	50.5%	1,896	1,260	1,338	1,609	1,706	1,576	1,804	1,800	1,938	2,007	2,059	2,112	2,208	2,181	1,477	1,546	1,624	1,641	1,292	1,284	1,119
Current Assets	125.5%	1,219	540	590	613	694	517	695	774	954	1,011	1,066	1,122	1,232	1,244	605	692	779	807	475	479	321
Cash Equivalents	259.7%	594	165	208	167	280	121	174	152	197	197	185	154	216	441	166	131	296	531	136	201	169
Inventory	-14.5%	31.00	36.00	32.00	27.00	22.00	15.00	15.00	15.00	16.00	16.00	16.00	16.00	19.00	19.00	18.00	19.00	19.00	17.00	17.00	16.00	16.00
Net PPE	2.4%	87.00	85.00	82.00	79.00	73.00	67.00	65.00	59.00	53.00	46.00	43.00	37.00	34.00	28.00	27.00	26.00	22.00	18.00	15.00	15.00	13.00
Goodwill	0%	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00	82.00
Liabilities	40.6%	2,714	1,931	1,917	2,066	2,053	1,803	1,986	1,890	1,937	1,902	1,862	1,819	1,726	1,670	904	1,017	1,029	978	803	771	768
Current Liabilities	22.6%	603	492	476	442	406	420	567	477	509	465	291	251	277	254	202	218	236	184	174	143	167
Long Term Debt	-50.4%	284	573	573	572	572	283	282	282	282	282	430	430	309	303	297	295	294	293	136	138	141
LT Debt, Current	-	-	-	-	-	-	-	150	150	150	149	-	-	8.00	-	18.00	20.00	20.00	20.00	20.00	17.00	12.00
LT Debt, Non Current	-50.4%	284	573	573	572	572	283	282	282	282	282	430	430	309	303	297	295	294	293	136	138	141
Shareholder's Equity	-Infinity%	-818	-	-	-	-347	-	-	-	1.00	105	197	293	482	511	572	529	594	664	489	513	351
Retained Earnings	-5.0%	-3,283	-3,127	-2,994	-2,795	-2,656	-2,486	-2,376	-2,224	-2,097	-1,954	-1,821	-1,702	-1,628	-1,554	-1,484	-1,303	-1,190	-1,112	-1,052	-1,011	-938
Additional Paid-In Capital	0.8%	2,466	2,447	2,417	2,340	2,305	2,223	2,184	2,153	2,124	2,093	2,064	2,034	-123	2,101	2,067	1,834	1,795	1,776	1,540	1,523	1,288
Shares Outstanding	0.3%	76.00	75.00	75.00	74.00	73.00	71.00	71.00	71.00	70.00	70.00	70.00	70.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,331	-	-	-	2,130	-	-	-	2,191	-	-	-	2,923	-	-	-	2,567	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-590.7%	-100	-14.52	-14.12	-29.49	-165	-38.04	-55.24	-97.40	-68.84	-51.19	-31.14	-100	-64.37	27.00	-74.81	-81.55	-10.21	-15.50	-30.52	-42.41	-15.14
Share Based Compensation	-38.7%	17.00	27.00	29.00	29.00	27.00	29.00	28.00	27.00	26.00	26.00	26.00	26.00	21.00	17.00	17.00	15.00	11.00	10.00	11.00	9.00	8.00
Cashflow From Investing	-219.0%	-94.42	-29.60	-23.75	-28.97	32.00	136	72.00	49.00	68.00	65.00	56.00	30.00	-208	-394	142	-101	-229	30.00	-38.17	-150	-24.60
Cashflow From Financing	18361.3%	620	3.00	18.00	4.00	303	-139	4.00	1.00	4.00	3.00	4.00	10.00	40.00	643	-32.92	18.00	2.00	382	3.00	226	4.00

PTCT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenue	$ 937,822	$ 698,801	$ 538,593
Operating expenses:
Cost of product sales, excluding amortization of acquired intangible assets	65,486	44,678	32,328
Amortization of intangible assets	222,635	116,554	54,751
Research and development	666,563	651,496	540,684
Selling, general and administrative	332,540	325,998	285,773
Change in the fair value of contingent consideration	(127,700)	(25,900)	(500)
Intangible asset impairment	217,800	33,384
Total operating expenses	1,377,324	1,146,210	913,036
Loss from operations	(439,502)	(447,409)	(374,443)
Interest expense, net	(129,180)	(90,871)	(86,022)
Other income (expense), net	10,130	(49,207)	(57,875)
Loss on extinguishment of debt	(137,558)
Loss before income tax benefit (expense)	(696,110)	(587,487)	(518,340)
Income tax benefit (expense)	69,506	28,470	(5,561)
Net loss attributable to common stockholders	$ (626,604)	$ (559,017)	$ (523,901)
Weighted-average shares outstanding:
Basic	74,838,392	71,728,634	70,466,393
Diluted	74,838,392	71,728,634	70,466,393
Net loss per share-basic and diluted (in dollars per share)
Basic	$ (8.37)	$ (7.79)	$ (7.43)
Diluted	$ (8.37)	$ (7.79)	$ (7.43)
Net product revenue
Revenues:
Revenue	$ 661,249	$ 535,228	$ 428,904
Collaboration revenue
Revenues:
Revenue	100,030	50,052	55,046
Royalty revenue
Revenues:
Revenue	168,856	113,521	54,643
Manufacturing revenue
Revenues:
Revenue	$ 7,687	$ 0	$ 0

PTCT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 594,001	$ 279,834
Marketable securities	282,738	130,871
Trade and royalty receivables, net	160,822	155,614
Inventory, net	30,577	21,808
Prepaid expenses and other current assets	150,491	105,658
Total current assets	1,218,629	693,785
Fixed assets, net	87,089	72,590
Intangible assets, net	379,497	705,891
Goodwill	82,341	82,341
Operating lease ROU assets	91,896	102,430
Deposits and other assets	36,246	48,582
Total assets	1,895,698	1,705,619
Current liabilities:
Accounts payable and accrued expenses	391,983	320,366
Deferred revenue	801	1,351
Operating lease liabilities- current	13,002	9,370
Finance lease liabilities- current	3,000	3,000
Liability for sale of future royalties - current	194,314	72,149
Total current liabilities	603,100	406,236
Long-term debt	284,213	571,722
Contingent consideration payable	36,300	164,000
Deferred tax liability	55,905	102,834
Operating lease liabilities- noncurrent	97,627	100,860
Finance lease liabilities- noncurrent	17,184	18,675
Liability for sale of future royalties- noncurrent	1,619,783	685,737
Other long-term liabilities	141	2,641
Total liabilities	2,714,253	2,052,705
Stockholders' deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022	75	72
Additional paid-in capital	2,466,233	2,305,020
Accumulated other comprehensive (loss) income	(1,285)	4,796
Accumulated deficit	(3,283,578)	(2,656,974)
Total stockholders' deficit	(818,555)	(347,086)
Total liabilities and stockholders' deficit	$ 1,895,698	$ 1,705,619

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

CEO	Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS
WEBSITE	ptcbio.com
INDUSTRY	Biotechnology
EMPLOYEES	1402

PTC Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for PTC Therapeutics Inc? What does PTCT stand for in stocks?

PTCT is the stock ticker symbol of PTC Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PTC Therapeutics Inc (PTCT)?

As of Mon Apr 22 2024, market cap of PTC Therapeutics Inc is 1.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers. The fair value of PTC Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PTC Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PTCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PTC Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTCT is over valued or under valued. Whether PTC Therapeutics Inc is cheap or expensive depends on the assumptions which impact PTC Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTCT.

What is PTC Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 22 2024, PTCT's PE ratio (Price to Earnings) is -3.18 and Price to Sales (PS) ratio is 2.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on PTC Therapeutics Inc's stock?

In the past 10 years, PTC Therapeutics Inc has provided 0.038 (multiply by 100 for percentage) rate of return.